Minerva medicaPub Date : 2023-12-01Epub Date: 2023-05-04DOI: 10.23736/S0026-4806.23.08474-4
Bright P Thilagar, Michael R Mueller, Ravindra Ganesh
{"title":"Perioperative cardiac risk reduction in non cardiac surgery.","authors":"Bright P Thilagar, Michael R Mueller, Ravindra Ganesh","doi":"10.23736/S0026-4806.23.08474-4","DOIUrl":"10.23736/S0026-4806.23.08474-4","url":null,"abstract":"<p><p>For patients undergoing nonemergent noncardiac surgery, care must be taken to identify patients at increased risk of major adverse cardiovascular events, as these remain a significant source of perioperative morbidity and mortality. Identification of at-risk patients requires careful attention to risk factors including assessment of functional status, medical comorbidities, and a medication assessment. After identification, to minimize perioperative cardiac risk, care should be taken through a combination of appropriate medication management, close monitoring for cardiovascular ischemic events, and optimization of pre-existing medical conditions. There are multiple society guidelines that aim to mitigate risk of cardiovascular morbidity and mortality in patients undergoing nonemergent noncardiac surgery. However, the rapid evolution of medical literature often creates gaps between the existing evidence and best practice recommendations. In this review, we aim to reconcile the recommendations made in the guidelines from the major cardiovascular and anesthesiology societies from the USA, Canada, and Europe, and to provide updated recommendations based on new evidence.</p>","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-12-01Epub Date: 2021-03-25DOI: 10.23736/S0026-4806.21.07124-X
Yuqing Shan, Xiangyuan Yin, Na Zhao, Jie Wang, Shouxiang Yang
{"title":"Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer.","authors":"Yuqing Shan, Xiangyuan Yin, Na Zhao, Jie Wang, Shouxiang Yang","doi":"10.23736/S0026-4806.21.07124-X","DOIUrl":"10.23736/S0026-4806.21.07124-X","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study is to explore the clinical value of serum tumor markers combined with dual-source CT scanning in the diagnosis of lung cancer.</p><p><strong>Methods: </strong>One hundred-two patients with lung cancer (malignant tumor group), 50 patients with benign lesions (benign control group) and 50 healthy patients (normal control group) were selected as the research objects. The levels of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and gastrin releasing peptide precursor 31-98 (Pro-GRP31-98) were detected using the electrochemiluminescence and enzyme-linked immunoassay in three groups of people. Simultaneously, Siemens' second-generation dual-source CT (Siemens AG, Munich, Germany) is used to scan the lungs of patients with lung cancer and benign lesions. Retrospective statistical analysis is utilized to explore the clinical value of serum tumor markers combined with dual-source CT examination in the diagnosis of lung cancer.</p><p><strong>Results: </strong>The levels of serum CEA, CYFRA21-1 and Pro-GRP31-98 in lung cancer patients were significantly higher than those in the benign control group and normal control group, and the difference was statistically significant (P<0.01). There was no statistical difference between the benign control group and the normal control group (P>0.05). The levels of serum CEA, CYFRA21-1, Pro-GRP31-98 had no significant correlation with the age, sex, and tumor site of lung cancer patients (P>0.05). However, the levels of serum CEA, CYFRA21-1, Pro-GRP31-98 have an obvious correlation with tumor size, clinical stage, histological type, combined pleural effusion, recurrence and metastasis after treatment (P<0.05). CT scans of 102 lung cancer patients showed 35 cases of central type, 67 cases of peripheral type, 71 cases with tumor diameter >5cm, 31 cases of ≤5cm and 67 cases of lymph node metastasis. The sensitivities of CEA, CYFRA21-1, Pro-GRP31-98, and dual-source CT in the diagnosis of lung cancer were 64.70%, 60.11%, 56.86% and 77.45%, and the accuracy was 75.00%, 72.37%, 69.74% and 82.89%, respectively. Compared with a single examination, the sensitivity and accuracy of combined examination for the diagnosis of lung cancer were significantly improved, which were 95.10% and 92.76%, respectively.</p><p><strong>Conclusions: </strong>Joint examinations can effectively improve the rate of lung cancer diagnosis.</p>","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25516945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-12-01Epub Date: 2022-07-05DOI: 10.23736/S0026-4806.22.08223-4
Juan Yu
{"title":"Partial response of Zercepac® plus capecitabine for postoperative multiple metastases of HER2-positive breast cancer.","authors":"Juan Yu","doi":"10.23736/S0026-4806.22.08223-4","DOIUrl":"10.23736/S0026-4806.22.08223-4","url":null,"abstract":"","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40469394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-12-01Epub Date: 2022-05-18DOI: 10.23736/S0026-4806.22.08131-9
Wantao Huang, Songhai Liu, Wenyan Li
{"title":"Finite element analysis of micro-implants containing threads in different bone types.","authors":"Wantao Huang, Songhai Liu, Wenyan Li","doi":"10.23736/S0026-4806.22.08131-9","DOIUrl":"10.23736/S0026-4806.22.08131-9","url":null,"abstract":"","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42118362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-10-01Epub Date: 2023-06-09DOI: 10.23736/S0026-4806.23.08509-9
Mohd Wahid, Arshad Jawed, Raju K Mandal, Mohammed Y Areeshi, Nahed A El-Shall, Ranjan K Mohapatra, Hardeep S Tuli, Kuldeep Dhama, Rinaldo Pellicano, Sharmila Fagoonee, Shafiul Haque
{"title":"Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.","authors":"Mohd Wahid, Arshad Jawed, Raju K Mandal, Mohammed Y Areeshi, Nahed A El-Shall, Ranjan K Mohapatra, Hardeep S Tuli, Kuldeep Dhama, Rinaldo Pellicano, Sharmila Fagoonee, Shafiul Haque","doi":"10.23736/S0026-4806.23.08509-9","DOIUrl":"10.23736/S0026-4806.23.08509-9","url":null,"abstract":"<p><p>The COVID-19 disease wreaked havoc all over the world causing more than 6 million deaths out of over 519 million confirmed cases. It not only disturbed the human race health-wise but also caused huge economic losses and social disturbances. The utmost urgency to counter pandemic was to develop effective vaccines as well as treatments that could reduce the incidences of infection, hospitalization and deaths. The most known vaccines that could help in managing these parameters are Oxford-AstraZeneca (AZD1222), Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) and Johnson & Johnson (Ad26.COV2.S). The effectiveness of AZD1222 vaccine in reducing deaths is 88% in the age group 40-59 years, touching 100% in the age group 16-44 years & 65-84 years. BNT162b2 vaccine also did well in reducing deaths due to COVID-19 (95% in the age group 40-49 years and 100% in the age group 16-44 years. Similarly, mRNA-1273 vaccine showed potential in reducing COVID-19 deaths with effectiveness ranging from 80.3 to 100% depending upon age group of the vaccinated individuals. Ad26.COV2.S vaccine was also 100% effective in reducing COVID-19 deaths. The SARS-CoV-2 emerging variants have emphasized the need of booster vaccine doses to enhance protective immunity in vaccinated individuals. Additionally, therapeutic effectiveness of Molnupiravir, Paxlovid and Evusheld are also providing resistance against the spread of COVID-19 disease as well as may be effective against emerging variants. This review highlights the progress in developing COVID-19 vaccines, their protective efficacies, advances being made to design more efficacious vaccines, and presents an overview on advancements in developing potent drugs and monoclonal antibodies for countering COVID-19 and emerging variants of SARS-CoV-2 including the most recently emerged and highly mutated Omicron variant.</p>","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9967890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-10-01Epub Date: 2021-09-03DOI: 10.23736/S0026-4806.21.07729-6
Chen Gao, Xiaorong Bai, Suisheng Yang, Xuanzhen Da, Xiaoqin Li, Shibo Wang, Xi Zhang
{"title":"Predictive value and significance of Ki67 Index in sentinel lymph node metastasis of early invasive breast cancer.","authors":"Chen Gao, Xiaorong Bai, Suisheng Yang, Xuanzhen Da, Xiaoqin Li, Shibo Wang, Xi Zhang","doi":"10.23736/S0026-4806.21.07729-6","DOIUrl":"10.23736/S0026-4806.21.07729-6","url":null,"abstract":"","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39397577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-10-01Epub Date: 2021-10-21DOI: 10.23736/S0026-4806.21.07881-2
Shanshan Chen, Jiankui Ye, Yanli Wang, Xiaoli Tang, Weiping Xie
{"title":"Analysis of clinical characteristics and detection of pathogens in patients with pulmonary tuberculosis complicated with fungal infection.","authors":"Shanshan Chen, Jiankui Ye, Yanli Wang, Xiaoli Tang, Weiping Xie","doi":"10.23736/S0026-4806.21.07881-2","DOIUrl":"10.23736/S0026-4806.21.07881-2","url":null,"abstract":"","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39535708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minerva medicaPub Date : 2023-10-01Epub Date: 2022-07-05DOI: 10.23736/S0026-4806.22.08214-3
Chang'an Wang
{"title":"Elimination of infusion-related reactions after the switch of Herceptin® with Zercepac®.","authors":"Chang'an Wang","doi":"10.23736/S0026-4806.22.08214-3","DOIUrl":"10.23736/S0026-4806.22.08214-3","url":null,"abstract":"","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40469393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}